In mouse models of PD, administration of IPA decreased the permeability of the intestinal barrier and blood–brain barrier (BBB), ameliorated inflammation, and improved dopaminergic neuronal function in a PXR-dependent manner, with a possible involvement of the Janus kinase 1 (JAK1)/STAT6 pathway [37]. The gene discussed is JAK1; the disease is Parkinson disease.